Breadth of Protection: Evaluating Long‑Term Immunogenicity, Cross‑Protection, and Dissemination Strategies of the ARPV/ZIKV Vaccine
Files
TR Number
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Zika virus (ZIKV) is a mosquito-borne Orthoflavivirus that is distributed throughout the Americas, Africa, and Asia. Zika virus has also been known to co-circulate with other Orthoflaviviruses such as West Nile, Dengue, Japanese encephalitis virus, and yellow fever virus. Our central goal is to produce a robust immunogenic vaccine against ZIKV. ARPV/ZIKV (Aripo-Zika) is a chimeric virus containing the prM and E proteins of ZIKV and the nonstructural proteins of Aripo virus (ARPV). Herein, we explore ARPV/ZIKV cross-protection against other Orthoflaviviruses, durability of protection and best dissemination strategies. Immune competent and immune compromised mice were vaccinated with ARPV/ZIKV and challenged with SPOV. Our data indicates SPOV is cross-protective against SPOV in both mouse models, but does not completely protect against all symptoms of disease. We also assessed the durability of protection afforded by ARPV/ZIKV in immune competent mice over ten months and assessed the best dissemination strategies for delivering the vaccine. Our results indicate ARPV/ZIKV completely protects against a ZIKV challenge ten months post vaccination. Also, ARPV/ZIKV was not compatible with Sf9 cells, which have been used for propagation of other vaccines; and the strategies used to lyophilize ARPV/ZIKV did not produce a uniform stable powder product. However, we did determine that ARPV/ZIKV can be concentrated and stored long-term for vaccine research and transport. Overall, our data indicate the chimeric vaccine platform continues to be a promising avenue for developing a vaccine for ZIKV and other Orthoflaviviruses.